C4 Therapeutics Inc. (CCCC)
NASDAQ · Healthcare
C4 Therapeutics Inc. Shareholder Equity 2021–2025
C4 Therapeutics Inc. annual/quarterly shareholder equity history from 2021 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- C4 Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 256.6M, a 18.80% increase year-over-year.
- C4 Therapeutics Inc. shareholder equity for 2025 were 256.6M, a 18.80% increase from 2024.
- C4 Therapeutics Inc. shareholder equity for 2024 were 216.0M, a 12.24% decrease from 2023.
- C4 Therapeutics Inc. shareholder equity for 2023 were 246.1M, a 14.91% decrease from 2022.
- C4 Therapeutics Inc. shareholder equity for 2022 were 289.2M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| C4 Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $257 |
| 2024 | $216 |
| 2023 | $246 |
| 2022 | $289 |
| 2021 | $390 |
| C4 Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $257 |
| 2024-12-31 | $216 |
| 2023-12-31 | $246 |
| 2022-12-31 | $289 |
| 2021-12-31 | $390 |
C4 Therapeutics Inc. Shareholder Equity — FAQ
C4 Therapeutics Inc. (CCCC) shareholder equity over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CCCC's shareholder equity history?
The chart and table above show C4 Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.